Research programme: inflammation therapeutics - Endo/Aurigene Oncology
Latest Information Update: 15 Jan 2024
Price :
$50 *
At a glance
- Originator Aurigene Discovery Technologies; Endo Pharmaceuticals
- Developer Aurigene Oncology; Endo Pharmaceuticals
- Class
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in India
- 22 Apr 2013 Preclinical trials in Inflammation in India (unspecified route)
- 31 Dec 2009 Early research in Inflammation in India (unspecified route)